325 related articles for article (PubMed ID: 26401053)
21. Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich's ataxia patient cells.
Vilema-Enríquez G; Quinlan R; Kilfeather P; Mazzone R; Saqlain S; Del Molino Del Barrio I; Donato A; Corda G; Li F; Vedadi M; Németh AH; Brennan PE; Wade-Martins R
J Biol Chem; 2020 Dec; 295(52):17973-17985. PubMed ID: 33028632
[TBL] [Abstract][Full Text] [Related]
22. Excision of the expanded GAA repeats corrects cardiomyopathy phenotypes of iPSC-derived Friedreich's ataxia cardiomyocytes.
Li J; Rozwadowska N; Clark A; Fil D; Napierala JS; Napierala M
Stem Cell Res; 2019 Oct; 40():101529. PubMed ID: 31446150
[TBL] [Abstract][Full Text] [Related]
23. Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia.
Greene E; Mahishi L; Entezam A; Kumari D; Usdin K
Nucleic Acids Res; 2007; 35(10):3383-90. PubMed ID: 17478498
[TBL] [Abstract][Full Text] [Related]
24. Friedreich ataxia patient tissues exhibit increased 5-hydroxymethylcytosine modification and decreased CTCF binding at the FXN locus.
Al-Mahdawi S; Sandi C; Mouro Pinto R; Pook MA
PLoS One; 2013; 8(9):e74956. PubMed ID: 24023969
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic promoter silencing in Friedreich ataxia is dependent on repeat length.
Chutake YK; Lam C; Costello WN; Anderson M; Bidichandani SI
Ann Neurol; 2014 Oct; 76(4):522-8. PubMed ID: 25112975
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription.
De Biase I; Chutake YK; Rindler PM; Bidichandani SI
PLoS One; 2009 Nov; 4(11):e7914. PubMed ID: 19956589
[TBL] [Abstract][Full Text] [Related]
27. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology.
Al-Mahdawi S; Pinto RM; Varshney D; Lawrence L; Lowrie MB; Hughes S; Webster Z; Blake J; Cooper JM; King R; Pook MA
Genomics; 2006 Nov; 88(5):580-90. PubMed ID: 16919418
[TBL] [Abstract][Full Text] [Related]
28. Complete FXN deletion in a patient with Friedreich's ataxia.
van den Ouweland AM; van Minkelen R; Bolman GM; Wouters CH; Becht-Noordermeer C; Deelen WH; Deelen-Manders JM; Ippel EP; Saris J; Halley DJ
Genet Test Mol Biomarkers; 2012 Sep; 16(9):1015-8. PubMed ID: 22691228
[TBL] [Abstract][Full Text] [Related]
29. Excision of Expanded GAA Repeats Alleviates the Molecular Phenotype of Friedreich's Ataxia.
Li Y; Polak U; Bhalla AD; Rozwadowska N; Butler JS; Lynch DR; Dent SYR; Napierala M
Mol Ther; 2015 Jun; 23(6):1055-1065. PubMed ID: 25758173
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional profiling of isogenic Friedreich ataxia neurons and effect of an HDAC inhibitor on disease signatures.
Lai JI; Nachun D; Petrosyan L; Throesch B; Campau E; Gao F; Baldwin KK; Coppola G; Gottesfeld JM; Soragni E
J Biol Chem; 2019 Feb; 294(6):1846-1859. PubMed ID: 30552117
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
Herman D; Jenssen K; Burnett R; Soragni E; Perlman SL; Gottesfeld JM
Nat Chem Biol; 2006 Oct; 2(10):551-8. PubMed ID: 16921367
[TBL] [Abstract][Full Text] [Related]
32. Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor.
Chutake YK; Lam CC; Costello WN; Anderson MP; Bidichandani SI
Nucleic Acids Res; 2016 Jun; 44(11):5095-104. PubMed ID: 26896803
[TBL] [Abstract][Full Text] [Related]
33. Neurobehavioral deficits of mice expressing a low level of G127V mutant frataxin.
Fil D; Conley RL; Zuberi AR; Lutz CM; Gemelli T; Napierala M; Napierala JS
Neurobiol Dis; 2023 Feb; 177():105996. PubMed ID: 36638893
[TBL] [Abstract][Full Text] [Related]
34. Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia.
Gottesfeld JM; Rusche JR; Pandolfo M
J Neurochem; 2013 Aug; 126 Suppl 1(0 1):147-54. PubMed ID: 23859350
[TBL] [Abstract][Full Text] [Related]
35. Analysis of Putative Epigenetic Regulatory Elements in the
Fernández-Frías I; Pérez-Luz S; Díaz-Nido J
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32408537
[TBL] [Abstract][Full Text] [Related]
36. FXN Promoter Silencing in the Humanized Mouse Model of Friedreich Ataxia.
Chutake YK; Costello WN; Lam CC; Parikh AC; Hughes TT; Michalopulos MG; Pook MA; Bidichandani SI
PLoS One; 2015; 10(9):e0138437. PubMed ID: 26393353
[TBL] [Abstract][Full Text] [Related]
37. Generation and characterization of iPSC lines from Friedreich's ataxia patient (FRDA) with GAA.TTC repeat expansion in the Frataxin (FXN) gene's first intron (IGIBi016-A) and a non-FRDA healthy control individual (IGIBi017-A).
Ahmad I; Kamai A; Zahra S; Kapoor H; Kumar Srivastava A; Faruq M
Stem Cell Res; 2024 Jun; 77():103382. PubMed ID: 38484450
[TBL] [Abstract][Full Text] [Related]
38. Beyond loss of frataxin: the complex molecular pathology of Friedreich ataxia.
Evans-Galea MV; Lockhart PJ; Galea CA; Hannan AJ; Delatycki MB
Discov Med; 2014 Jan; 17(91):25-35. PubMed ID: 24411698
[TBL] [Abstract][Full Text] [Related]
39. Role of mismatch repair enzymes in GAA·TTC triplet-repeat expansion in Friedreich ataxia induced pluripotent stem cells.
Du J; Campau E; Soragni E; Ku S; Puckett JW; Dervan PB; Gottesfeld JM
J Biol Chem; 2012 Aug; 287(35):29861-72. PubMed ID: 22798143
[TBL] [Abstract][Full Text] [Related]
40. Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy.
Marmolino D; Acquaviva F
Cerebellum; 2009 Sep; 8(3):245-59. PubMed ID: 19165552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
